+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Molecular Cancer Therapeutics. Strategies for Drug Discovery and Development. Edition No. 1

  • ID: 2175575
  • Book
  • April 2004
  • 368 Pages
  • John Wiley and Sons Ltd
Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development.
This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer. Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.
Note: Product cover images may vary from those shown


Chapter 1. Introduction (G. Prendergast).

Chapter 2. Molecular Cancer Therapeutics: Will the Promise Be Fulfilled? (B. Teicher).

Chapter 3. Cancer Genetics and Drug Target Selection (G. Zhang & W. Kaelin).

Chapter 4. RNA Interference in Mammals: Journey to the Center of Human Disease (P. Paddison & G. Hannon).

Chapter 5. Applications and Issues for Tissue Arrays in Target and Drug Discovery (E. Jonasch, K. Do, C. Logothetis, & T. McDonnell).

Chapter 6. Protein Transduction Strategies for Target and Mechanism Validation (S. Ezhevsky & S. Dowdy).

Chapter 7. Drug Screening: Assay Development Issues (S. Carroll, J. Inglese, S. Mao, & D. Olson).

Chapter 8. Gene Microarray Technologies for Cancer Drug Discovery and Development (R. te Poele, P. Clarke, & P. Workman).

Chapter 9. Transgenic Mouse Models of Cancer (T. Bowen & A. Wynshaw-Boris).

Chapter 10. Transgenic versus Xenograft Mouse Models of Cancer: Utility and Issues (M. Liu, W. Bishop, Y. Wang, & P. Kirschmeier).

Chapter 11. Pharmacodynamic Assays in Cancer Drug Discovery: From Preclinical Validation to Clinical Trial Monitoring (R. Lobell, N. Kohl, & L. Sepp-Lorenzino).

Chapter 12. Pharmacokinetic and Toxicology Issues in Cancer Drug Discovery and Development (P. Benfield & B. Car).

Chapter 13. Clinical Development Issues (S. Averbuch, M. Wolf, B. El-Rayes, & P. LoRusso).

Chapter 14. Intellectual Property and Commercialization Issues in Drug Discovery (L. Malseed).


Note: Product cover images may vary from those shown
George C. Prendergast Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, and Thomas Jefferson University, Jefferson Medical College, Philadelphia, Pennsylvania, USA.
Note: Product cover images may vary from those shown